Libtayo

News

NICE says Libtayo can be used for advanced cervical cancer

New NICE guidance means that around 90 UK women with cervical cancer should be eligible for treatment with Regeneron's Libtayo each year.

News

Regeneron's Libtayo stakes out new territory in skin cancer

Regeneron's Libtayo has become the first checkpoint inhibitor to be cleared by the FDA as an adjuvant treatment for cutaneous squamous cell carcinoma.

News

ASCO 25: Regeneron hails Libtayo's adjuvant data in CSCC

Regeneron's PD-1 inhibitor Libtayo hits the mark where MSD's Keytruda missed in a form of non-melanoma skin cancer.

News

EC approves Regeneron's Libtayo for advanced cervical cancer

Regeneron has announced that the European Commission (EC) has approved Libtayo (cemiplimab) as a monotherapy for the treatment of adult patients with second-line recurrent or metastatic cer

News

ESMO21: Libtayo extends survival in first-line NSCLC, challe...

There's no shortage of cancer immunotherapies trying to knock Merck & Co's Keytruda off the top of the tree in previously-untreated non-small cell lung cancer (NSCLC).

News

Sanofi and Regeneron eye Libtayo challenge to Keytruda in fi...

Sanofi and Regeneron's latecomer checkpoint inhibitor Libtayo has largely been protected from heavyweight competition in its first niche markets, but now looks set to for a toe-to-toe conte

NICE says Libtayo can be used for advanced cervical cancer

Regeneron's Libtayo stakes out new territory in skin cancer

ASCO 25: Regeneron hails Libtayo's adjuvant data in CSCC

EC approves Regeneron's Libtayo for advanced cervical cancer

ESMO21: Libtayo extends survival in first-line NSCLC, challe...

Sanofi and Regeneron eye Libtayo challenge to Keytruda in fi...

EMA advisors say CSL's Tavneos should be pulled from sale

Discover a new era of healthcare panel engagement: Grounded ...

Libtayo

Editor's Picks